Amelogenin is a negative regulator of osteoclastogenesis via downregulation of RANKL, M-CSF and fibronectin expression in osteoblasts

Miyuki Nishiguchi, Kenji Yuasa, Kan Saito, Emiko Fukumoto, Aya Yamada, Tomokazu Hasegawa, Keigo Yoshizaki, Yoko Kamasaki, Kazuaki Nonaka, Taku Fujiwara, Satoshi Fukumoto

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Amelogenin is a novel enamel matrix protein. Knockout mice showed enhanced osteoclast formation and resorption of tooth cementum. This study investigated the effects of amelogenin on osteoclastogenesis. In co-cultures with calvaria osteoblasts and purified bone marrow cells, amelogenin inhibited osteoclastogenesis dramatically. Furthermore, amelogenin inhibited the expression of receptor activator of nuclear factor κB ligand (RANKL), macrophage-colony stimulating factor (M-CSF) and fibronectin in osteoblasts, while RANKL expression was induced by fibronectin and inhibited by treatment with fibronectin small interfering RNA. These results suggest that the inhibitory effects of amelogenin on osteoclastogenesis lead to downregulation of RANKL, M-CSF and fibronectin production in osteoblasts.

Original languageEnglish
Pages (from-to)237-243
Number of pages7
JournalArchives of Oral Biology
Volume52
Issue number3
DOIs
Publication statusPublished - 2007 Mar
Externally publishedYes

Keywords

  • Amelogenin
  • Fibronectin
  • M-CSF
  • Osteoblast
  • Osteoclast
  • RANKL

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Dentistry(all)
  • Cell Biology

Fingerprint Dive into the research topics of 'Amelogenin is a negative regulator of osteoclastogenesis via downregulation of RANKL, M-CSF and fibronectin expression in osteoblasts'. Together they form a unique fingerprint.

  • Cite this